SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3559 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1832RE: OPHT (Roche) and Fovista Does anyone have idea what are Roche financial oblMiljenko Zuanic-11/17/2015
1831John wrote sound arguments, still there is more issue to consider or have in minMiljenko Zuanic111/11/2015
1830Pretty good MDCO/ALNY bear argument from John LaMattina: forbes.comDewDiligence_on_SI-11/11/2015
1829The lower expectations.. better for "investors"..., because competitorMiljenko Zuanic-11/11/2015
1828Small Rx numbers, company hope that "free" Rx will turn (later, in fewMiljenko Zuanic-11/11/2015
1827What's everyone's thought on Q4 Praulent sales at 4 mil? I see no majorFelix B-11/10/2015
1826Thnx for update, seams that Repatha have some 'traction".Miljenko Zuanic-11/10/2015
1825Harvard Pilgrim’s Repatha contract: siliconinvestor.comDewDiligence_on_SI-11/9/2015
1824bi-specific for cancer...(sanofi optioned in for this platform)Miljenko Zuanic-11/6/2015
1823As I stated before I don't think bispecific is advantageous when you can coaFelix B-11/5/2015
1822THNX, I am bit surprise that REGN is not going after those targets, with their bMiljenko Zuanic-11/5/2015
1821FWIW GHENT, Belgium, 5 November 2015 - Ablynx [Euronext Brussels: ABLX] today anigel bates-11/5/2015
1820So with all the good news today, why the drop?Felix B-11/4/2015
1819Dupilumab BLA should be at FDA by mid-16 and approved by early-17.Miljenko Zuanic-11/4/2015
1818What is FOP? What is Fibrodysplasia Ossificans Progressiva (FOP)? One of the raBiotech Jim-11/4/2015
1817BLA for sarilumab submitted. Ph3 for RSV mAb now ongoing. Dupilumab Ph 3 dataBiotech Jim-11/4/2015
1816$371 M for RofW is a NICE number! :-)Miljenko Zuanic-11/4/2015
1815Regeneron earnings... November 4, 2015 Regeneron Reports Third Quarter 2015 Biotech Jim-11/4/2015
1814That is in theory. In vitreous humor/retina space VEGF/PDGF are somehow "loMiljenko Zuanic-10/28/2015
1813They are both secreted proteins no? Hence for better efficancy dual admin wouldFelix B-10/28/2015
18123Q15 ex-US Lucentis sales reported by NVS: $485M, -8% YoY in constant currency: DewDiligence_on_SI-10/27/2015
1811RE: PDGF/VEGF Ophthotech completed enrollment in second P3, result in 4Q-16. bMiljenko Zuanic-10/26/2015
1810Isn't Ang2/VEGF receptor expressed on same/similar cells? I am for PDGF/VEGFMiljenko Zuanic-10/23/2015
1809If both targets on same cell I agree a bispecific would be idea but since those Felix B-10/23/2015
1808Hetero-dimerization of the receptors, one act on mode of other one,....IF sufficMiljenko Zuanic-10/22/2015
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News